Bio-Techne
| Company type | Public company |
|---|---|
| Industry | Biotechnology |
| Founded | 1976 |
| Founder | Dr. Roger C. Lucas |
| Headquarters | Minneapolis, Minnesota, U.S. |
Key people | Chuck Kummeth, President & CEO James Hippel, CFO Robert V. Baumgartner, Chairman |
| Products | Proteins Reagents Diagnostic instruments |
| Revenue |  US$738 million (2020) |
| US$229 million (2020) | |
| Total assets | US$2.027 billion (2020) |
| Total equity | US$1.381 billion (2020) |
Number of employees | 2,300 (2020) |
| Website | bio-techne |
| Footnotes / references [1] | |
Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets. The company's brands include R&D Systems, ProteinSimple, and Novus Biologicals.[1]
History
The company was founded in 1976 by Dr. Roger C. Lucas as Research and Diagnostic Systems, Inc. In 1985, it merged into Techne Corporation and became a public company.[1]
In March 2013, Charles (Chuck) Kummeth was named chief executive officer of the company.[2]
In July 2013, the company acquired Bionostics for $104 million.[3][4]
In February 2014, the company changed its name to Bio-Techne.[5]
In April 2014, the company agreed to acquire Shanghai PrimeGene Bio-Tech Company (PrimeGene).[6][7]
In July 2014, the company acquired Novus Biologicals for $60 million.[8][9][10]
In August 2014, the company acquired ProteinSimple for $300 million.[11]
In November 2014, the company agreed to acquire CyVek for $60 million plus up to an additional $135 million in earn-out payments.[12][13][14]
In June 2015, the company agreed to acquire Cliniqa Corporation.[15][16]
In March 2016, the company acquired Zephyrus Biosciences.[17][18][19]
In July 2016, the company acquired Space Import-Export.[20]
In August 2016, company acquired Advanced Cell Diagnostics for $250 million plus an additional $75 million in possible milestone payments.[21][22][23]
In September 2017, the company acquired Trevigen.[24][25]
In January 2018, the company acquired Atlanta Biologicals.[26][27]
In June 2018, the company agreed to acquire Quad Technologies.[28][29]
In August 2018, the company acquired Exosome Diagnostics for $250 million plus up to an additional $325 million in milestone payments.[30]
In June 2019, the company acquired B-Mogen.[31][32]
In April 2021, the company acquired Asuragen for $215 million plus up to an additional $105 million in milestone payments.[33]
In June 2022, the business announced it would acquire Namocell Inc.[34]
References
- ^ a b c "Bio-Techne Corporation 2020 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- ^ "Board Of Directors Appoints Charles Kummeth As Chief Executive Officer And Director Of Techne Corporation" (Press release). PR Newswire. March 18, 2013.
- ^ Resende, Patricia (July 23, 2013). "Techne Corp. completes $104M cash purchase of Bionostics, names new CTO". American City Business Journals.
- ^ "Local company news". Star Tribune. July 22, 2013.
- ^ "Techne Corporation Announces New Trade Name, Bio-Techne". PR Newswire. February 10, 2014.
- ^ "Bio-Techne Announces Acquisition Agreement". PR Newswire. April 15, 2014.
- ^ Hammerand, Jim (April 15, 2014). "Techne has deal to buy Chinese genetics firm". American City Business Journals.
- ^ "Bio-Techne Acquires Novus Biologicals for $60M". genengnews.com. July 3, 2014.
- ^ "Bio-Techne Announces Agreement to Acquire Novus Biologicals for $60M". The Wall Street Journal. July 3, 2014.
- ^ "Bio-Techne Announces Agreement To Acquire Novus Biologicals". PR Newswire. July 2, 2014.
- ^ "Bio-Techne Announces ProteinSimple Acquisition Completion" (Press release). PR Newswire. August 1, 2014.
- ^ "Bio-Techne Announces Agreement To Acquire CyVek" (Press release). PR Newswire. November 4, 2014.
- ^ "Bio-Techne to Acquire CyVek for Up to $195M+". genengnews.com. November 5, 2014.
- ^ "Wallingford's CyVek acquired by Minnesota company". New Haven Register. November 13, 2014.
- ^ "Bio-Techne Corporation Agrees to Acquire Cliniqa Corporation" (Press release). PR Newswire. June 5, 2015.
- ^ "Cliniqa Now Owned by Bio-Techne". genengnews.com. June 5, 2015.
- ^ "Bio-Techne Corporation Agrees to Acquire Zephyrus Biosciences, Inc" (Press release). PR Newswire. March 21, 2016.
- ^ "Bio-Techne Acquires Zephyrus Biosciences". genengnews.com. March 21, 2016.
- ^ "Bio-Techne Acquires Zephyrus Biosciences". The Wall Street Journal. March 22, 2016.
- ^ "Bio-Techne Acquires Space Import-Export And Strengthens European Leadership Team" (Press release). PR Newswire. July 1, 2016.
- ^ "Bio-Techne Corporation Completed its Acquisition of Advanced Cell Diagnostics" (Press release). PR Newswire. August 1, 2016.
- ^ "Bio-Techne to Acquire Advanced Cell Diagnostics for Up to $325M". genengnews.com. July 7, 2016.
- ^ Al Idrus, Amirah (July 7, 2016). "MedTech Bio-Techne shells out $250M for Advanced Cell Diagnostics". FierceBiotech.
- ^ "Bio-Techne Acquires Trevigen Inc" (Press release). PR Newswire. September 5, 2017.
- ^ Bakolia, Ravikash (September 5, 2017). "Bio-Techne acquires privately held Trevigen". S&P Global.
- ^ "Bio-Techne Acquires Atlanta Biologicals Inc" (Press release). PR Newswire. January 2, 2018.
- ^ Carlson, Joe (January 2, 2018). "Bio-Techne buys Atlanta Biologicals in cash deal". Associated Press.
- ^ "Bio-Techne To Acquire Quad Technologies" (Press release). PR Newswire. June 7, 2018.
- ^ Bakolia, Ravikash (June 7, 2018). "Bio-Techne to acquire privately held Quad Technologies". S&P Global.
- ^ "Bio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc" (Press release). PR Newswire. August 1, 2018.
- ^ "Bio-Techne To Acquire B-MoGen Biotechnologies Inc" (Press release). PR Newswire. June 4, 2019.
- ^ Wittenberg, Alex (June 5, 2019). "Bio-Techne acquires Minneapolis gene-editing firm formed at U of M". American City Business Journals.
- ^ "Bio-Techne Completes Acquisition of Asuragen, Inc" (Press release). PR Newswire. April 6, 2021.
- ^ "Bio-Techne to Acquire Namocell".
External links
- Official website
- Business data for Bio-Techne Corporation: